PGNY
Get informed when a big investor buys or sells
+ FollowOvervalued by 76.3% based on the discounted cash flow analysis.
| Market cap | $2.00 Billion |
|---|---|
| Enterprise Value | $1.89 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.68 |
| Beta | 0.91 |
| Outstanding Shares | 80,920,993 |
| P/E Ratio | 30.55 |
|---|---|
| PEG | 50.16 |
| Price to Sales | 1.67 |
| Price to Book Ratio | 5.0 |
| Enterprise Value to Revenue | 1.46 |
| Enterprise Value to EBIT | 18.6 |
| Enterprise Value to Net Income | 27 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4963▲ 26.74% |
|---|---|
| Total Calls | 67,900▼ 2.86% |
| Total Puts | 33,700▲ 110.63% |
Holdings and activity of institutional investors.
| Ownership % | 93.61%▲ 0.27% |
|---|---|
| Total Invested | $1.36B▼ 33.99% |
| Investors Holding | 294▼ 23.00% |
No data
This committee directly influences corporate tax structures and the tax treatment of benefits, impacting Progyny's financial performance and the attractiveness of employer-sponsored health benefits that Progyny manages.
This committee controls taxation and entitlement spending. Tax policy regarding employer-sponsored benefits and corporate taxation directly impacts Progyny's profitability and the demand for its services, while broad healthcare policy changes also affect its market.
This committee directly regulates health policy, labor laws, and aspects of the FDA. As a benefits management company, Progyny is highly susceptible to changes in employer-sponsored benefits regulations, healthcare mandates, and oversight of fertility-related drugs/devices.